New Herceptin early breast cancer regimens

Copyright © F. Hoffmann-La Roche Ltd
Copyright © F. Hoffmann-La Roche Ltd

Herceptin (trastuzumab) has had its licence for use in HER2-positive early breast cancer extended.

In addition to use following surgery, chemotherapy and radiotherapy, it is now also recommended in:

  • combination with paclitaxel or docetaxel following adjuvant chemotherapy with doxorubicin and cyclophosphamide, or;
  • combination with docetaxel and carboplatin.

In early breast cancer patients, cardiac monitoring should be performed before treatment initiation, every 3 months during treatment and every 6 months for 2 years from the last dose of Herceptin.

View Herceptin drug record

Further Information: Roche Products Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more